



Goody Agahi

Partner

Orange County Los Angeles
+1.949.623.3525

Goody.Agahi@klgates.com

OVERVIEW

Goodarz (Goody) Agahi is a corporate partner in the firm's Orange County and Los Angeles offices. His practice focuses on complex business transactions, including mergers and acquisitions, leveraged buyouts, recapitalizations, and financings.

Goody has structured, negotiated and completed transactions in a wide variety of industries, including, apparel, consumer products, medical devices, pharmaceuticals, food and beverage, software and technology.

PROFESSIONAL BACKGROUND

Prior to joining the firm, Goody served as a partner at a national law firm where he focused his practice on complex business transactions, including mergers and acquisitions, leveraged buyouts, restructurings, recapitalizations, and financings. He has represented clients in matters in various industries. He also has acted as general outside counsel for clients, assisting with their day-to-day legal needs.

EDUCATION

- B.A., University of California at Los Angeles (UCLA)
- J.D., Georgetown University Law Center
- LL.M., Georgetown University Law Center

ADMISSIONS

- Bar of California

NEWS & EVENTS

- 25 October 2021, K&L Gates Advises Beyond Yoga in Acquisition by Levi Strauss & Co.

- 15 April 2019, K&L Gates Further Bolsters Corporate Practice with Addition of Orange County, Los Angeles Partner

MEDIA MENTIONS

- "West Coast Lumber Expands Into Structural Component Manufacturing With Stone Truss Acquisition," *M&A Navigator*, 3 August 2023
- "Deal snapshot: Endeavor Fire Protection Acquires High Sierra Fire Protection to Enter Western US Market," *M&A Navigator*, 2 August 2023

AREAS OF FOCUS

- Mergers and Acquisitions
- Emerging Growth and Venture Capital
- Private Equity Transactions

INDUSTRIES

- Financial Services
- Private Equity

REPRESENTATIVE EXPERIENCE

- Represented Malbon Golf, Inc. in its Series A investment by Avenir Growth Capital.
- Represented I Am Beyond, LLC dba Beyond Yoga in connection with its acquisition by Levi Strauss & Co. (NYSE: LEVI).
- Represented Drips, LLC in connection with a minority recapitalization by Accel-KKR.
- Represented Environmental Intelligence, LLC in connection with its acquisition by Montrose Environmental Group, Inc. (NYSE: MEG).
- Represented PreZero US, Inc. in connection with multiple acquisitions, including the acquisition of Roplast Industries, LLC.
- Represented Winc, Inc. in connection with its acquisition of substantially all of the assets of Natural Merchants, Inc.
- Represented Paradigm Holdings Group, LLC in connection with a majority recapitalization by Hamilton Robinson Capital Partners.
- Represented Aerospace Engineering, Corp. in connection with its acquisition by Trive Capital Partners.

- Represented Permit Advisors, Inc. in connection with its acquisition by Milrose Consultants.
- Represented Boardriders Inc. in connection with its sale of the Xcel wetsuit brand to ZG Collective.
- Represented Blenders Eyewear, LLC in connection with its acquisition by Safilo Group.
- Represented RPM Consolidated Services, Inc. in connection with its acquisition by Odyssey Logistics & Technology Corporation.
- Represented Host Compliance LLC in connection with its acquisition by Granicus, LLC.
- Represented CAP Diagnostics, LLC (dba Pathnostics) in connection with its acquisition by Water Street Healthcare Partners.
- Represented Host Compliance, LLC in connection with its acquisition of Bear Cloud Software, LLC.
- Represented TravisMathew, LLC in connection with its acquisition by Callaway Golf Company.
- Represented Omega Biosystems, Inc. in connection with its acquisition by BD Biosciences.
- Represented Gatekeeper Systems, Inc. in connection with its acquisition by Hammond, Kennedy, Whitney & Company, Inc.
- Represented Blockade Medical, LLC in connection with its acquisition by Balt, Inc.
- Represented Santen Pharmaceuticals in connection with its acquisition of Merck's ophthalmic assets.
- Represented Questcor Pharmaceuticals in connection with its acquisition of rights to develop Synacthen from Novartis Pharma.